MACC Fund Commits $11.5 Million to Propel Pediatric Cancer Research at Versiti Blood Research Institute
MWN-AI** Summary
The Midwest Athletes Against Childhood Cancer (MACC) Fund has made a significant commitment of $11.5 million to enhance pediatric cancer research at the Versiti Blood Research Institute. This investment aims to improve treatment outcomes for children with leukemia and other blood disorders, solidifying the ongoing partnership between the two organizations. Becky Pinter, president and CEO of the MACC Fund, emphasized the importance of this collaboration, stating, "Kids deserve better treatment options. Kids deserve to be kids."
The multiyear investment will bolster existing high-impact research in areas such as pediatric leukemia biology, immune system discovery, and translational science. It will enhance the capacity for research, facilitate the recruitment and retention of investigators, and advance clinical studies that aim to translate laboratory insights into effective treatments for children.
Pediatric leukemia primarily consists of two types: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). While ALL has a survival rate of around 90%, AML poses a greater threat, with nearly half of those diagnosed not surviving. Versiti researchers are currently working on innovative approaches including precision oncology immunotherapies, CAR T-cell therapy, and artificial intelligence applications in therapy development.
The partnership coincides with a major expansion at the Versiti Blood Research Institute, which will provide additional infrastructure and resources for research, aimed for completion in late 2026. Chris Miskel, president and CEO of Versiti, highlighted that community investment in research directly contributes to better futures for children battling cancer.
The MACC Fund, established in 1976, has historically mobilized community support for childhood cancer research, contributing nearly $90 million over the years. This latest investment reinforces Milwaukee's status as a leader in pediatric cancer research, providing hope for families across the nation.
MWN-AI** Analysis
The MACC Fund’s recent commitment of $11.5 million towards pediatric cancer research at the Versiti Blood Research Institute represents a strategic opportunity for investors looking to support social responsibility while potentially capitalizing on advancements in the biotech sector.
This funding will accelerate research into pediatric leukemia, an area that has critical unmet needs, as it targets the most prevalent form of childhood cancer—Acute Lymphoblastic Leukemia (ALL). Despite significant advancements with survival rates nearing 90%, there remains substantial room for improvement, particularly in understanding and treating Acute Myeloid Leukemia (AML), which has devastating outcomes. The MACC Fund’s investment will aid in developing next-generation therapies, including CAR T-cell therapy and precision oncology immunotherapies, which may lead to breakthrough treatments and commercial products.
Investors should note that breakthroughs in pediatric cancer research often translate into significant market opportunities, as successful strategies can extend to broader oncology markets. The emphasis on reducing treatment toxicity and enhancing efficacy represents a crucial shift towards patient-centered therapeutic approaches that appeal to a growing segment of the market prioritizing quality of life in treatment plans.
Additionally, Versiti's impending expansion of its research facilities signals an increase in capacity and capability, which could enhance its innovative output. As the organization strengthens its research capabilities, it may attract further research partnerships and grants, improving its financial sustainability and market position.
In light of these developments, investors should consider companies engaged in supporting or partnering with research initiatives focused on pediatric and hematologic cancers, as well as those leveraging cutting-edge technologies like artificial intelligence in drug discovery. The MACC Fund’s commitment is not just a philanthropic effort; it symbolizes an evolving landscape in cancer treatment that offers considerable potential for long-term growth and societal impact.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
MILWAUKEE, March 3, 2026 /PRNewswire/ -- The MACC Fund has committed $11.5 million to advance pediatric cancer research at the Versiti Blood Research Institute, strengthening a long-standing partnership dedicated to improving outcomes for children facing leukemia and other blood disorders.
"The MACC Fund is proud to partner with the Versiti Blood Research Institute to spotlight and accelerate Versiti's pioneering work in leukemia biology, immune discovery, and translational research. Kids deserve better treatment options. Kids deserve to be kids. By expanding our support, we're empowering researchers to move discoveries from the lab to life-changing treatments, faster, smarter, and with renewed hope for every child to thrive," said Becky Pinter, president and CEO of the MACC Fund.
The multiyear investment will accelerate high-impact research already underway in pediatric leukemia biology, immune system discovery and translational science that moves insights from the lab toward the bedside. The commitment will support investigator recruitment and retention, expand translational research capacity, advance active clinical and laboratory studies, and provide sustained funding to pursue emerging scientific opportunities in pediatric leukemia.
There are two primary types of pediatric leukemia: acute lymphoblastic leukemia, or ALL, and the rarer acute myeloid leukemia, or AML. ALL is the most common cancer among children, with more than 3,000 new cases diagnosed annually in the United States. While survival rates for ALL are approximately 90 percent, AML remains devastating, with nearly half of diagnosed children dying from the disease.
Versiti researchers are working to change that trajectory.
Current areas of study include:
- Developing next-generation precision oncology immunotherapies
- Using CAR T-cell therapy to train patients' immune systems to fight cancer
- Building a basic understanding and clinical use of natural killer cells
- Reducing toxicity in existing treatments
- Applying artificial intelligence to bioinformatics to create more targeted, precise therapies
Versiti currently has four faculty-level investigators leading pediatric leukemia research projects, with plans to add one to two more in the next 12 months. The institute is conducting two active clinical and translational studies and six active scientific studies, supported by 20 research staff members. In the past two years alone, investigators have published 54 peer-reviewed publications.
The multiyear investment will accelerate high-impact research already underway in pediatric leukemia biology, immune system discovery and translational science that moves insights from the lab toward the bedside. The commitment will support investigator recruitment and retention, expand translational research capacity, advance active clinical and laboratory studies, and provide sustained funding to pursue emerging scientific opportunities in pediatric leukemia.
This expanded capacity aligns with the 79,000-square-foot Versiti Blood Research Institute expansion, providing the space and infrastructure to scale collaboration, equipment, and pilot projects that will translate discoveries into next-generation therapies for children. The expansion is on track to be completed and open to researchers in late 2026.
"When a community chooses to invest in research, it invests in a child's future. The MACC Fund's bold $11.5 million commitment will fuel leading-edge scientific work at Versiti that has the potential to change outcomes for children facing cancer. We are grateful for this partnership and committed to delivering breakthrough discoveries for families in need," said Chris Miskel, president and CEO of Versiti.
The MACC Fund has long mobilized community support to fuel childhood cancer research. This investment reflects a shared commitment to strengthening scientific capacity, supporting leading investigators, and sustaining discovery that improves survival rates while reducing treatment toxicity for children. This partnership underscores Milwaukee's leadership in pediatric cancer research while contributing to discoveries that have the potential to impact children nationwide.
About the MACC Fund
The MACC Fund (Midwest Athletes Against Childhood Cancer, Inc.) is a non-profit founded in 1976 with a mission to fund a cure for childhood cancer and related blood disorders by providing funding for research. Over the years, the MACC Fund has contributed nearly $90 million toward groundbreaking research in these areas. In addition to funding research, the MACC Fund raises awareness and engages the community to bring hope to children and families.
About Versiti
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of healthcare partners nationally. The organization is a 501(c)(3) not-for-profit headquartered in Milwaukee, with more than 2,700 employees at locations in Illinois, Indiana, Michigan, Ohio, Texas and Wisconsin. Versiti provides innovative, value-added solutions in transfusion medicine, transplantation, and blood-related diseases to meet the needs of its customers. The collective efforts result in improved patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide. For more information, visit Versiti.org.
SOURCE Versiti, Inc.
FAQ**
How does the collaboration between the MACC Fund and Versiti Blood Research Institute fit within the broader trends in pediatric cancer research investments by organizations like Douglas Emmett Inc. DEI?
What specific outcomes or breakthroughs does the MACC Fund anticipate from its $11.5 million commitment to pediatric cancer research at Versiti, considering the ongoing efforts of Douglas Emmett Inc. DEI in healthcare innovation?
In what ways will the expanded capacity of the Versiti Blood Research Institute, supported by the MACC Fund's investment, align with Douglas Emmett Inc. DEI’s objectives in enhancing research infrastructure for pediatric health?
How will the MACC Fund's funding improve treatment options for pediatric leukemia, and what lessons can be drawn from this initiative for similar partnerships in the healthcare sector, including those involving Douglas Emmett Inc. DEI?
**MWN-AI FAQ is based on asking OpenAI questions about Douglas Emmett Inc. (NYSE: DEI).
NASDAQ: DEI
DEI Trading
-1.44% G/L:
$9.95 Last:
819,933 Volume:
$10.16 Open:
